Association of Low Serum Levels of Apolipoprotein A-I With Adverse Outcomes in Patients With Nonischemic Heart Failure

Journal of Cardiac Failure

Volumn 13, Issue 4, 2007, Pages 247-253

  Iwaoka, Masahiko ^a   Obata, Jyun Ei ^a   Abe, Makoto ^a   Nakamura, Takamitsu ^a   Kitta, Yoshinobu ^a   Kodama, Yasushi ^a   Kawabata, Ken Ichi ^a   Takano, Hajime ^a   Fujioka, Daisuke ^a   Saito, Yukio ^a   Kobayashi, Tsuyoshi ^a   Hasebe, Hideyuki ^a   Kugiyama, Kiyotaka ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Apolipoprotein A I; heart failure; high density lipoprotein; inflammation

Indexed keywords

AMIODARONE; APOLIPOPROTEIN A1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SPIRONOLACTONE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BODY MASS; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; IMMUNOASSAY; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TURBIDIMETRY;

AGED; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; LIPOPROTEINS, HDL; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 34248560027     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.01.007     Document Type: Article

References (21)

1. Ansell B.J., Watson K.E., Fogelman A.M., Navab M., and Fonarow G.C. High-density lipoprotein function recent advances. J Am Coll Cardiol 46 (2005) 1792-1798
2. Nofer J.R., Kehrel B., Fobker M., Levkau B., Assmann G., and von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161 (2002) 1-16
3. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 95 (2004) 764-772
4. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., and Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256 (1986) 2835-2838
5. Maciejko J.J., Holmes D.R., Kottke B.A., Zinsmeister A.R., Dinh D.M., and Mao S.J. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med 309 (1983) 385-389
6. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 (2002) 988-998
7. Jankowska E.A., Ponikowski P., Piepoli M.F., Banasiak W., Anker S.D., and Poole-Wilson P.A. Autonomic imbalance and immune activation in chronic heart failure-pathophysiological links. Cardiovasc Res 70 (2006) 434-445
8. Korantzopoulos P., Galaris D., Papaioannides D., and Siogas K. The possible role of oxidative stress in heart failure and the potential of antioxidant intervention. Med Sci Monit 9 (2003) RA140-RA145
9. Munger M.A., Johnson B., Amber I.J., Callahan K.S., and Gilbert E.M. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 77 (1996) 723-727
10. Ho K.K., Anderson K.M., Kannel W.B., Grossman W., and Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88 (1993) 107-115
11. Sakai Y., Itakura K., Kanada T., Ebata N., Suga K., Aikawa H., et al. Quantitation of apolipoprotein A-I in pooled human serum by single radial immunodiffusion and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 137 (1984) 1-7
12. Kugiyama K., Doi H., Motoyama T., Soejima H., Misumi K., Kawano H., et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 97 (1998) 2519-2526
13. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 17 (1957) 237-246
14. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., and Stevenson L.W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35 (2000) 681-689
15. Teichholz L.E., Kreulen T., Herman M.V., and Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 37 (1976) 7-11
16. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldman A.M., Francis G.S., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 104 (2001) 2996-3007
17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 (2003) S5-S20
18. Pearson T.A., Blair S.N., Daniels S.R., Eckel R.H., Fair J.M., Fortmann S.P., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002) 388-391
19. Hyka N., Dayer J.M., Modoux C., Kohno T., Edwards III C.K., Roux-Lombard P., et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 97 (2001) 2381-2389
20. Opie L.H., Commerford P.J., Gersh B.J., and Pfeffer M.A. Controversies in ventricular remodelling. Lancet 367 (2006) 356-367
21. Barter P.J., and Rye K.A. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med 259 (2006) 447-454